Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15096528 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Komatsu S, Ikebe M (2004) ZIP kinase is responsible for the phosphorylation of myosin II and necessary for cell motility in mammalian fibroblasts. J Cell Biol 165, 243-54 15096528
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T19-p - MRLC1 (mouse) ▲
Orthologous residues
MRLC1 (human): T19‑p, MRLC1 (mouse): T19‑p, MRLC1 (rat): T19‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), NRK (fibroblast), REF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse, rat
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE smMLCK (chicken)
KINASE DAPK3 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE DAPK3 (human) transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, immunodepletion of upstream enzyme, phospho-antibody, siRNA inhibition of enzyme

S20-p - MRLC1 (mouse) ▲
Orthologous residues
MRLC1 (human): S20‑p, MRLC1 (mouse): S20‑p, MRLC1 (rat): S20‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), NRK (fibroblast), REF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse, rat
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE smMLCK (chicken)
KINASE DAPK3 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE DAPK3 (human) transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, immunodepletion of upstream enzyme, phospho-antibody, siRNA inhibition of enzyme

T19-p - MRLC1 (rat) ▲
Orthologous residues
MRLC1 (human): T19‑p, MRLC1 (mouse): T19‑p, MRLC1 (rat): T19‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), NRK (fibroblast), REF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse, rat
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE DAPK3 (human) transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, immunodepletion of upstream enzyme, phospho-antibody, siRNA inhibition of enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Y27632 decrease
ML-7 decrease
wortmannin no change compared to control

S20-p - MRLC1 (rat) ▲
Orthologous residues
MRLC1 (human): S20‑p, MRLC1 (mouse): S20‑p, MRLC1 (rat): S20‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), NRK (fibroblast), REF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse, rat
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE DAPK3 (human) transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, immunodepletion of upstream enzyme, phospho-antibody, siRNA inhibition of enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Y27632 decrease
ML-7 decrease
wortmannin no change compared to control


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.